Challenges of adherence management in human immunodeficiency virus pharmacotherapy

Canadian Journal of Clinical Pharmacology

Volumn 10, Issue 4, 2003, Pages 189-195

  Park Wyllie, Laura Y ^a,b   Phillips, Elizabeth J ^c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Adherence; Human immunodeficiency virus; Medication; Toxicity

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANXIETY DISORDER; CHRONIC DISEASE; COGNITIVE DEFECT; CONFUSION; DEMOGRAPHY; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIARRHEA; DIET RESTRICTION; DIZZINESS; DRUG COST; DRUG MONITORING; DYSLIPIDEMIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMPAIRED GLUCOSE TOLERANCE; LACTIC ACIDOSIS; LIFESPAN; LIPODYSTROPHY; LIVER TOXICITY; MENTAL DISEASE; MORBIDITY; MORTALITY; MYOPATHY; NAUSEA; NIGHTMARE; OSTEOPENIA; OSTEOPOROSIS; PANCREATITIS; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PILL; RASH; REVIEW; SELF REPORT; SOCIAL ASPECT; VOMITING;

EID: 0842278741     PISSN: 1198581X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
2. Miller LG, Hays RD. Measuring adherence to antiretroviral medications in clinical trials. HIV Clin Trials 2000;1:36-46.
3. Low-Beer S, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr Hum Retrovirol 2000;23:360-1.
4. Hogg RS, Yip B, Chan K, et al. Nonadherence to triple combination therapy is predictive of AIDS progression and death in HIV-positive men and women. 7th Conference on Retrovirus and Opportunistic Infections, January 30-February 2, 2000.
5. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995;267:483-9.
6. Bartlett JA. Addressing the challenges of adherence. J Acquir Immune Defic Syndr 2002;29(Suppl 1):S2-10.
7. Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: Comparison of self-report and electronic monitoring. Clin Infect Dis 2001;33:1417-23.
8. Grimes RM, Easling J, Ray S. Nonadherence to protease inhibitors 758 patients from three separate cohorts of HIV infected patients. [Abs ThPeB4983]. 13th International AIDS Conference. Durban, South Africa, July 9-14, 2000.
9. Paech V, Lorenzen T, Stoehr A, Plattenberg A. Adherence to HAART: Why is it so difficult? Arch Intern Med 2002;162:1197-8.
10. Nieuwkerk PT, Sprangers MA, Burger DM, et al. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med 2001;161:1962-8.
11. Tuldra A, Fumaz CR, Ferrer MJ, et al. Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly acitve antiretroviral therapy. J Acquir Immune Defic Syndr 2000;25:221-8.
12. Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001;134:968-77.
13. Mannerheimer S, Friedland G, Matts J. Self-reported antiretroviral adherence correlates with HIV viral load and declines over time. [Abst TuOrB421]. 13th International AIDS Conference. Durban, South Africa, July 9-14, 2000.
14. Carrieri P, Cailleton V, LeMoing V, et al. The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO cohort. J Acquir Immune Defic Syndr 2001;28:232-9.
15. Duran S, Spire B, Raffi F, et al. Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clin Trials 2001;2:38-45.
16. Grimes RM, Lal L, Lewis ST. Frequency of medical history items, drug interactions, and lifestyle characteristics that may interfere with antiretroviral medications. HIV Clin Trials 2002;3:161-7.
17. Fogarty L, Roter D, Larson S, Burke J, Gillespie J, Levy R. Patient adherence to HIV medication regimens: A review of published and abstract reports. Patient Educ Courts 2002;46:93-108.
18. Singh N, Berman SM, Swindells S, et al. Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy. Clin Infect Dis 1999;29:824-30.
19. Bangsberg DR, Charlebois ED, Grant R. Low levels of adherence do not increase risk of HIV drug resistance mutations. [Abst 546]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections. Seattle, Washington, February 24-28, 2002.
20. Bangsberg DR, Hecht, FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000;14:357-66.
21. Bangsber DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001;15:1181-3.
22. Garcia de Olalla P, Knobel H, Carmona A, Guelar A, Lopez-Colomes JL, Cayla LA. Impact of adherence and highly active antiretroviral therapy, on survival in HIV-infected patients. J Acquir Immune Defic Syndr 2002;30:105-10.
23. Casado JL, Knobel H, Sabido R. Initial adherence level predicts antiretroviral efficacy, clinical progression, and mortality: Results of a prospective, nation-based survey over 3000 patients. [Abstract 11719]. In: Abstracts of the 41st Interscience Conference of Antimicrobial Agents and Chemotherapy. Chicago, December 16-19, 2001,
24. Vanhove GF, Schapiro JM, Winters MA, Merigan TC, Blaschke TR. Patient compliance and drug failure in protease inhibitor monotherapy. JAMA 1996;276:1955-6.
25. Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA 1998;279:930-7.
26. Scalera A, Bayoumi A, Oh P. Clinical and economic implications of non-adherence to HAART in HIV infection. Dis Manag Health Outcomes 2002;10:85-91.
27. Reynolds NR. Initiatives to get HIV-infected patients to adhere to their treatment regimens. Drug Benefit Trends 1998;10:23-5,29-30,32.
28. Dunbar-Jacob J, Mortimer-Stephens MK. Treatment adherence in chronic disease. J Clin Epidemiol 2001;54(Suppl 1):S57-60.
29. Montessori V, Heath KV, Yip B. Predictors of adherence with triple combination antiretroviral therapy. [Abstract 74]. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, January 30-February 2, 2000.
30. Stone VE, Adelson-Mitty J, Duefield CA. Adherence to protease inhibitor (PI) therapy in clinical practice: Usefulness of demographics, attitudes and knowledge as predictors. [Abstract 32337]. 12th World AIDS Conference. Geneva, June 28-July 3, 1998.
31. Chesney MA, Folkman S. Psychological impact of HIV disease and implications for intervention. Psychiatr Clin North Am 1994;17:163-82.
32. Cinti SK. Adherence to antiretrovirals in HIV disease: Adequate adherence can not be predicted in those with higher socio-economic status, educational levels and lack of substance abuse history. AIDS Read 2000;10:709-17.
33. Chesney MA, Iokovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 2000;12:255-66.
34. Catz SL, Kelly JA, Bogart LM, Benotsch EG, McAuliffe TL. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol 2000;19:124-33.
35. Catz SL, McClure JB, Jones GN, Brantley PJ. Predictors of outpatient medical appointment attendance among persons with HIV. AIDS Care 1999;11:361-72.
36. Bakken S, Holzemer WL, Brown MA, et al. Relationships between perception with health care provider and demographic characteristics, health status and adherence to therapeutic regimen in persons with HIV/AIDS. AIDS Patient Care STDS 2000;14:189-97.
37. Safren SA, Otto MW, Worth JL, et al. Two strategies to increase adherence to HIV antiretroviral medication: life-steps and medication monitoring. Behav Res Ther 2001;39:1151-62.
38. Gordillo V, del Amo J, Soriano V, Gonzalez-Lahoz J. Sociodemographic and psychogical variables influencing adherence to antiretroviral therapy. AIDS 1999;13:1763-9.
39. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310.
40. Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquired Immune Defic Syndr 2001;28:445-9.
41. Gallant JG, Block DS. Adherence to antiretroviral regimens in HIV-infected patients: results of a survey among physicians and patients. J Int Assoc Physicians AIDS Care 1998;4:32-5.
42. Bond WS, Hussar DA. Detection methods and strategies for improving medication compliance. Am J Hosp Pharm 1991;48:1978-88.
43. Golin C, Liu H, Hays R. Self-reported adherence to protease inhibitors substantially overestimates an objective measure. [Abstract 95]. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, June 31-February 4, 1999,
44. Arnsten J, Demas P, Gourevitch M. Adherence and viral load in HIV-infected drug users: comparison of self-report and medication event monitors (MEMS). [Abstract 69]. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco; January 30-February 2, 2000.
45. Miller LG, Liu H, Hays RD, et al. How well do clinicians estimate patients' adherence to combination antiretroviral therapy? J Gen Intern Med 2002;17:1-11.
46. Miller LG, Hays RD. Adherence to combination antiretroviral therapy: synthesis of the literature and clinical implications. AIDS Read 2000;10:177-85.
47. DiMatteo MR, DiNicola DD. Achieving Patient Compliance. New York: Pergamon Press, 1982.
48. Roth HP, Caron HS. Accuracy of doctors' estimates and patients' statements on adherence to a drug regimen. Clin Pharmacol Ther 1978;23:361-70.
49. Gilbert JR, Evans CE, Haynes, RB, Tugwell P. Predicting compliance with a regimen of digoxin therapy in family practice. CMAJ 1980;123:119-22.
50. Back D, Gatti G, Fletcher C, et al. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS 2002;16(Suppl 1):S1-37.
51. Burger DM, Hugen PWH, Droste J, et al. Therapeutic drug monitoring of nelfinavir 1250 mg bid in treatment-naïve patients improves therapeutic outcome after 1 year: results from ATHENA. [Abstract 6.2b]. 2nd International Workshop on Clinical Pharmacology of HIV Therapy. Noordwijk, The Netherlands, April, 2002.
52. Park-Wyllie LY, Antoniou T, Bayoumi, AM et al. Effectiveness of patient support strategies for improving HAART adherence in HIV-infected individuals: A systematic review of controlled trials. [Abstract 236P]. In: Program and abstracts of the 11th Annual Canadian Conference on HIV/AIDS Research. Winnipeg, April 25-28, 2002.
53. Collier A, Ribaudo H, Feinberg J. Randomized study of telephone calls to improve adherence to antiretroviral therapy. [Abstract 540]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections. Seattle, February 24-25, 2002.
54. Pradier C, Bentz L, Spire B. Counseling interventions can improve adherence to highly active antiretroviral therapy: Results of a French prospective controlled study. [Abstract 541]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections. Seattle, February 24-25, 2002.
55. Balfour L, Hamel M, Kowal J. The STAART Adherence Intervention Study: Improving patients' readiness for starting HIV medications - An update. [Abstract 476P]. In: Program and abstracts of the 11th Annual Canadian Conference on HIV/AIDS Research. Winnipeg, April 25-28, 2002.
56. Tuldra A, Fumaz CR, Ferrer MJ, et al. Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2000;25:221-8.
57. US Department of Health and Human Services. 2001 Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Rockville, MD: HIV/AIDS Treatment Information Service. 〈 http://aidsinfo.nih.gov/guidelines/〉 (Version current at December 12, 2003).
58. Wohl DA. Adherence to HIV therapy - Helping the medicine go down. Conference reports for NATAP. 〈 http://www.natap.org/2002/9retro/day17.htm〉 (Version current at December 12, 2003).
59. Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau E Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS 2001;15:1369-77.